| Literature DB >> 32071595 |
Chunnan Piao1, Mei Tian1, Hongjun Gao2, Yanxiao Gao3, Jianlei Ruan1, Lina Wu1, Gang Gao1, Lirong Yi1, Jianxiang Liu1.
Abstract
OBJECTIVE: To analyze changes in immune functions by detecting lymphocyte subsets in the peripheral blood of residents in the vicinity of radon from hot springs.Entities:
Keywords: hormesis; low dose; lymphocyte subsets; peripheral blood; radon hot springs
Year: 2020 PMID: 32071595 PMCID: PMC6997968 DOI: 10.1177/1559325820902338
Source DB: PubMed Journal: Dose Response ISSN: 1559-3258 Impact factor: 2.658
Comparison of Basic Data in the 2 Groups.
| Group | Number | Gender | Age | Smoking | Alcohol Consumption | BMI (kg/m2) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| F | M | ≤45 | >45 | No | Yes | No | Yes | ≤18.5 | 18.5-24 | ≥24 | ||
| Control | 51 | 30 | 21 | 25 | 26 | 40 | 11 | 35 | 16 | 0 | 17 | 34 |
| Radon | 61 | 38 | 23 | 35 | 26 | 49 | 12 | 41 | 20 | 0 | 27 | 34 |
| χ2 | 0.140 | 0.780 | 0.061 | 0.025 | 1.391 | |||||||
|
| 0.708 | 0.377 | 0.805 | 0.873 | 0.238 | |||||||
Abbreviations: BMI, body mass index; F, female; M, male.
Regression Analysis of Lymphocyte Subsets in Peripheral Blood.
| Lymphocyte Subset | Variable |
| Sb | β |
|
|
|---|---|---|---|---|---|---|
| CD45 | Constant | 96.964 | 1.041 | – | 93.186 | .000a |
| Radon exposure | −0.033 | 0.014 | −0.214 | −2.303 | −.083 | |
| CD3+ | Constant | 13.641 | 0.788 | – | 17.312 | .000a |
| Radon exposure | 0.001 | 0.008 | 0.001 | 0.001 | .999 | |
| CD4−CD8+ | Constant | 47.366 | 1.436 | – | 32.987 | .000a |
| Radon exposure | −0.038 | 0.015 | −0.232 | −2.497 | .014a | |
| CD4+CD8− | Constant | 41.255 | 1.509 | – | 27.347 | .000a |
| Radon exposure | 0.019 | 0.016 | 0.112 | 1.177 | .242 | |
| CD4+/CD8+ | Constant | 0.966 | 0.108 | – | 8.920 | .000a |
| Radon exposure | 0.002 | 0.001 | 0.178 | 1.900 | .060 | |
| TCR/CD3 | Constant | 83.782 | 2.038 | – | 43.884 | .000a |
| Radon exposure | −0.055 | 0.027 | −0.192 | −2.047 | .043a | |
| LYMPH# | Constant | 2.275 | 0.082 | – | 27.867 | .000a |
| Radon exposure | 0.000 | 0.001 | 0.026 | 0.266 | .790 | |
| LYMPH% | Constant | 32.178 | 1.143 | – | 28.147 | .000a |
| Radon exposure | 0.003 | 0.012 | 0.026 | 0.268 | .789 |
Abbreviations: “-” indicates no data; b, regression coefficients; β, standardized partial regression coefficient; Sb, standard error of regression coefficients.
a A significant difference.
Percentage Change in Lymphocyte Subsets in the Radon Hot Spring Group.
| Lymphocyte Subset | Group | N | % (x ± SD) |
|
|
|---|---|---|---|---|---|
| CD45 | Control | 51 | 97.53 ± 1.272 | 2.303 | −.023a |
| Radon | 61 | 94.14 ± 10.446 | |||
| CD4+/CD8+ | Control | 51 | 0.93 ± 0.387 | −2.201 | .03a |
| Radon | 61 | 1.26 ± 1.041 | |||
| TCR/CD3 | Control | 51 | 83.78 ± 19.112 | 2.047 | .043a |
| Radon | 61 | 89.43 ± 5.259 | |||
| LYMPH# | Control | 49 | 2.260 ± 0.578 | −0.485 | .629 |
| Radon | 56 | 2.317 ± 0.622 |
Abbreviation: SD, standard deviation.
a A significant difference.
Comparison of the Percentage Change in Lymphocyte Subsets by Mann-Whitney U Test.
| Lymphocyte Subset | Group | N | P50 |
|
|
|---|---|---|---|---|---|
| CD3+ | Control | 51 | 12.90 | −0.140 | .888 |
| Radon | 61 | 13.50 | |||
| CD4−CD8+ | Control | 51 | 48.00 | −2.141 | .032a |
| Radon | 61 | 43.80 | |||
| CD4+CD8- | Control | 51 | 38.80 | −0.964 | .335 |
| Radon | 61 | 42.30 | |||
| LYMPH% | Control | 49 | 50.35 | −0.835 | .404 |
| Radon | 56 | 55.32 |
a A significant difference.
Comparison of the Prevalence of Rheumatism and Cancer Between Radon Hot Spring Area and Control Area.
| Disease Name | Radon | Control | χ2 |
|
|---|---|---|---|---|
| Rheumatism | 14.447 | <.001a | ||
| Prevalence | 34 | 21 | ||
| Nonprevalence | 21 037 | 35 741 | ||
| Cancer | 6.751 | .009a | ||
| Prevalence | 23 | 72 | ||
| Nonprevalence | 21 048 | 35 690 | ||
| Rheumatism + cancer | 0.055 | .814 | ||
| Prevalence | 57 | 93 | ||
| Nonprevalence | 21 014 | 35 669 |
a A significant difference. Prevalence, number of sick people; nonprevalence, number of people not ill; rheumatism + cancer, sum of the number of patients with rheumatism and cancer.